Actively Recruiting
Phase II Study of Nimotuzumab Combined With Toripalimab, Gemcitabine, and Cisplatin for First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-09-19
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of combining nimotuzumab and toripalimab with the gemcitabinecisplatin GP chemotherapy regimen as a first-line treatment for patients with recurrent or distant metastatic nasopharyngeal carcinoma. This phase II clinical trial is designed to better understand how well this combination works and its safety profile in this patient population. Participants will receive treatment cycles lasting three weeks each. The chemotherapy regimen includes up to six cycles, while nimotuzumab and toripalimab are continued until disease progression. Treatment is based on the TGP regimen toripalimab, gemcitabine, and cisplatin combined with nimotuzumab. This study follows a single-center, prospective, single-arm design. During the study, patients will have regular follow-up visits where researchers will monitor treatment response using RECIST 1.1 and irRECIST criteria, and track any adverse events with CTCAE 5.0 standards. The main outcome measured is the objective response rate at three months. Secondary outcomes include progression-free survival, overall survival, disease control rate, duration of response, and adverse events over multiple years. Participants can expect a thorough and ongoing evaluation of their response and safety throughout the trial.
CONDITIONS
Brief Title
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
Research Team
Y
Yang Sheng
H
He Xiaohui
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here